Long COVID-19 and its scientific prevention and control

LIU Qiao; DU Min; LIU Jue; LIU Min

doi:10.16462/j.cnki.zhjbkz.2022.07.001

Volume 26 Issue 7

Jul. 2022

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2022 > 26(7): 745-749

LIU Qiao, DU Min, LIU Jue, LIU Min. Long COVID-19 and its scientific prevention and control[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2022, 26(7): 745-749. doi: 10.16462/j.cnki.zhjbkz.2022.07.001

Citation:

LIU Qiao, DU Min, LIU Jue, LIU Min. Long COVID-19 and its scientific prevention and control[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2022, 26(7): 745-749. doi: 10.16462/j.cnki.zhjbkz.2022.07.001

Citation:

PDF( 884 KB)

Long COVID-19 and its scientific prevention and control

doi: 10.16462/j.cnki.zhjbkz.2022.07.001

Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China

LIU Qiao and DU Min contributed equally to this article

Funds:

National Natural Science Foundation of China 72122001

National Natural Science Foundation of China 71934002

National Key Research and Development Project of China 2021ZD0114101

National Key Research and Development Project of China 2021ZD0114104

National Key Research and Development Project of China 2021ZD0114105

Capital Health Development Scientific Research Project 2021-1G-4281

More Information

Corresponding author: LIU Jue, E-mail: jueliu@bjmu.edu.cn; LIU Min, E-mail: liumin@bjmu.edu.cn
Received Date: 2022-04-24
Rev Recd Date: 2022-05-11

Available Online: 2022-07-19

Publish Date: 2022-07-10

Abstract

Abstract

Global literature have reported that individuals who have recovered from the acute phase of COVID-19 may suffer from persistent symptoms, namely long COVID-19, also known as the post-COVID-19 condition. WHO defined that long COVID-19 occurs in individuals with a history of SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms and that last for at least 2 months and cannot be explained by an alternative diagnosis. Symptoms of long COVID-19 include fatigue, headache dyspnea and so on, affecting multiple systems such as neurological, psychiatric, respiratory, cardiovascular and gastrointestinal systems. Based on the existing evidence, it is suggested to strengthen scientific research on long COVID-19, persist in a "dynamic COVID-zero strategy" currently to reduce infections, accelerate vaccination coverage, and carry out early monitoring and intervention of long COVID-19, to cope with the long-term disease and economic burden caused by long COVID-19.
- SARS-CoV-2,
- Long COVID-19,
- Post-COVID-19 condition,
- Prevention and control

FullText(HTML)

References(50)

References

[1]	Worldometer. COVID-19 coronavirus pandemic[EB/OL]. (2022-04-22)[2022-04-24]. https://www.worldometers.info/coronavirus/.
[2]	Garg M, Maralakunte M, Garg S, et al. The conundrum of 'Long-COVID-19': a narrative review[J]. Int J Gen Med, 2021, 14: 2491-2506. DOI: 10.2147/ijgm.S316708.
[3]	Cabrera martimbianco AL, Pacheco RL, Bagattini ÂM, et al. Frequency, signs and symptoms, and criteria adopted for long COVID-19: a systematic review[J]. Int J Clin Pract, 2021, 75(10): e14357. DOI: 10.1111/ijcp.14357.
[4]	Yan Z, Yang M, Lai CL. Long COVID-19 syndrome: a comprehensive review of its effect on various organ systems and recommendation on rehabilitation plans[J]. Biomedicines, 2021, 9(8): 966. DOI: 10.3390/biomedicines9080966.
[5]	Soriano JB, Murthy S, Marshall JC, et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus[J]. Lancet Infect Dis, 2022, 22(4): e102-e107. DOI: 10.1016/S1473-3099(21)00703-9.
[6]	World Health Organization. Coronavirus disease (COVID-19) science conversation[EB/OL]. (2022-04-13)[2022-04-24]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/media-resources/science-in-5.
[7]	National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19[M]. London: National Institute for Health and Care Excellence, 2020.
[8]	The Lancet. Facing up to long COVID-19[J]. Lancet, 2020, 396(10266): 1861. DOI: 10.1016/s0140-6736(20)32662-3.
[9]	Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID-19[J]. Nature medicine, 2021, 27(4): 626-631. DOI: 10.1038/s41591-021-01292-y.
[10]	Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China[J]. JAMA Neurol, 2020, 77(6): 683-690. DOI: 10.1001/jamaneurol.2020.1127.
[11]	Douaud G, Lee S, Alfaro-almagro F, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank[J]. Nature, 2022, 604(7907): 697-707. DOI: 10.1038/s41586-022-04569-5.
[12]	Lechien JR, Chiesa-estomba CM, De siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study[J]. Eur Arch Otorhinolaryngol, 2020, 277(8): 2251-2261. DOI: 10.1007/s00405-020-05965-1.
[13]	de Melo GD, Lazarini F, Levallois S, et al. COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters[J]. Sci Transl Med, 2021, 13(596): eabf8396. DOI: 10.1126/scitranslmed.abf8396.
[14]	Shelton JF, Shastri AJ, Fletez-brant K, et al. The UGT2A1/UGT2A2 locus is associated with COVID-19-related loss of smell or taste[J]. Nat Genet, 2022, 54(2): 121-124. DOI: 10.1038/s41588-021-00986-w.
[15]	Taquet M, Geddes JR, Husain M, et al. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records[J]. Lancet Psychiatry, 2021, 8(5): 416-427. DOI: 10.1016/s2215-0366(21)00084-5.
[16]	Magnúsdóttir I, Lovik A, Unnarsdóttir A B, et al. Acute COVID-19 severity and mental health morbidity trajectories in patient populations of six nations: an observational study[J]. Lancet Public Health, 2022, 7(5): e406-e416. DOI: 10.1016/s2468-2667(22)00042-1.
[17]	Xie Y, Xu E, Al-aly Z. Risks of mental health outcomes in people with COVID-19: cohort study[J]. BMJ, 2022, 376: e068993. DOI: 10.1136/bmj-2021-068993.
[18]	Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic[J]. Lancet Psychiatry, 2020, 7(7): 611-627. DOI: 10.1016/s2215-0366(20)30203-0.
[19]	Mazza MG, Palladini M, De Lorenzo R, et al. One-year mental health outcomes in a cohort of COVID-19 survivors[J]. J Psychiatr Res, 2021, 145: 118-124. DOI: 10.1016/j.jpsychires.2021.11.031.
[20]	Carfì A, Bernabei R, Landi F, et al. Persistent symptoms in patients after acute COVID-19[J]. JAMA, 2020, 324(6): 603-605. DOI: 10.1001/jama.2020.12603.
[21]	Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study[J]. Clin Microbiol Infect, 2021, 27(1): 89-95. DOI: 10.1016/j.cmi.2020.09.023.
[22]	Wu X, Liu X, Zhou Y, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study[J]. Lancet Respir Med, 2021, 9(7): 747-754. DOI: 10.1016/s2213-2600(21)00174-0.
[23]	Bouteleux B, Henrot P, Ernst R, et al. Respiratory rehabilitation for COVID-19 related persistent dyspnoea: a one-year experience[J]. Respir Med, 2021, 189: 106648. DOI: 10.1016/j.rmed.2021.106648.
[24]	Fumagalli C, Zocchi C, Tassetti L, et al. Factors associated with persistence of symptoms 1 year after COVID-19: a longitudinal, prospective phone-based interview follow-up cohort study[J]. Eur J Intern Med, 2022, 97: 36-41. DOI: 10.1016/j.ejim.2021.11.018.
[25]	Wang Y, Dong C, Hu Y, et al. Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: a longitudinal study[J]. Radiology, 2020, 296(2): e55-e64. DOI: 10.1148/radiol.2020200843.
[26]	Garg M, Gupta P, Maralakunte M, et al. Diagnostic accuracy of CT and radiographic findings for novel coronavirus 2019 pneumonia: systematic review and meta-analysis[J]. Clin Imaging, 2021, 72: 75-82. DOI: 10.1016/j.clinimag.2020.11.021.
[27]	Mo X, Jian W, Su Z, et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge[J]. Eur Respir J, 2020, 55(6): 2001217. DOI: 10.1183/13993003.01217-2020.
[28]	Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19)[J]. JAMA Cardiol, 2020, 5(7): 819-824. DOI: 10.1001/jamacardio.2020.1096.
[29]	Xie Y, Xu E, Bowe B, et al. Long-term cardiovascular outcomes of COVID-19[J]. Nat Med, 2022, 28(3): 583-590. DOI: 10.1038/s41591-022-01689-3.
[30]	Huang L, Zhao P, Tang D, et al. Cardiac involvement in patients recovered from COVID-2019 identified using magnetic resonance imaging[J]. JACC Cardiovasc Imaging, 2020, 13(11): 2330-2339. DOI: 10.1016/j.jcmg.2020.05.004.
[31]	Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19)[J]. JAMA Cardiol, 2020, 5(11): 1265-1273. DOI: 10.1001/jamacardio.2020.3557.
[32]	Rajpal S, Tong MS, Borchers J, et al. Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection[J]. JAMA Cardiol, 2021, 6(1): 116-118. DOI: 10.1001/jamacardio.2020.4916.
[33]	石永言. 病例报告和系统综述表明临床诊断新型冠状病毒肺炎后儿童或受到类似成人的长期影响[J]. 国际儿科学杂志, 2021, 48(3): 206. DOI: 10.3760/cma.j.issn.1673-4408.2021.03.103. Shi YY. Case report and systematic review indicate the long-term effects of clinically diagnosed new coronavirus pneumonia on children or similar adults[J]. Int J Pediatr, 2021, 48(3): 206. DOI: 10.3760/cma.j.issn.1673-4408.2021.03.103.
[34]	Katsoularis I, Fonseca-Rodríguez O, Farrington P, et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after COVID-19: nationwide self-controlled cases series and matched cohort study[J]. BMJ, 2022, 377: e069590. DOI: 10.1136/bmj-2021-069590.
[35]	Kariyawasam JC, Jayarajah U, Riza R, et al. Gastrointestinal manifestations in COVID-19[J]. Trans R Soc Trop Med Hyg, 2021, 115(12): 1362-1388. DOI: 10.1093/trstmh/trab042.
[36]	Cheung KS, Hung IFN, Chan PPY, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis[J]. Gastroenterology, 2020, 159(1): 81-95. DOI: 10.1053/j.gastro.2020.03.065.
[37]	Penner J, Abdel-Mannan O, Grant K, et al. 6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: a retrospective cohort study[J]. Lancet Child Adolesc Health, 2021, 45(7): 473-482. DOI: 10.1016/s2352-4642(21)00138-3.
[38]	Wu Y, Guo C, Tang L, et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples[J]. Lancet Gastroenterol Hepatol, 2020, 5(5): 434-435. DOI: 10.1016/s2468-1253(20)30083-2.
[39]	McMahon DE, Gallman AE, Hruza GJ, et al. Long COVID in the skin: a registry analysis of COVID-19 dermatological duration[J]. Lancet Infect Dis, 2021, 21(3): 313-314. DOI: 10.1016/s1473-3099(20)30986-5.
[40]	Suchonwanit P, Leerunyakul K, Kositkuljorn C. Cutaneous manifestations in COVID-19: lessons learned from current evidence[J]. J Am Acad Dermatol, 2020, 83(1): e57-e60. DOI: 10.1016/j.jaad.2020.04.094.
[41]	Wan KH, Lui GCY, Poon KCF, et al. Ocular surface disturbance in patients after acute COVID-19[J]. Clin Exp Ophthalmol, 2022, 10. DOI: 10.1111/ceo.14066.
[42]	Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study[J]. Lancet Diabetes Endocrinol, 2022, 10(5): 311-321. DOI: 10.1016/s2213-8587(22)00044-4.
[43]	Anwar S, Acharya S, Shabih S, et al. Acute Limb Ischemia in COVID-19 Disease: a mysterious coagulopathy[J]. Cureus, 2020, 12(7): e9167. DOI: 10.7759/cureus.9167.
[44]	Acharya S, Anwar S, Siddiqui FS, et al. Renal artery thrombosis in COVID-19[J]. IDCases, 2020, 22: e00968. DOI: 10.1016/j.idcr.2020.e00968.
[45]	Fernandez CE, Franz CK, Ko JH, et al. Imaging review of peripheral nerve injuries in patients with COVID-19[J]. Radiology, 2021, 298(3): e117-e130. DOI: 10.1148/radiol.2020203116.
[46]	梁万年, 刘民, 刘珏, 等. 我国新型冠状病毒肺炎疫情防控的"动态清零"策略[J]. 中华医学杂志, 2022, 102(4): 239-242. DOI: 10.3760/cma.j.cn112137-20211205-02710. Liang WN, Liu M, Liu J, et al. The dynamic COVID-zero strategy on prevention and control of COVID-19 in China[J]. National Med J China. 2022, 102(4): 239-242. DOI: 10.3760/cma.j.cn112137-20211205-02710.
[47]	Heidi L. Can drugs reduce the risk of long COVID? What scientists know so far[J]. Nature, 2022, 604(1): 20-21. DOI: 10.1038/d41586-022-00823-y.
[48]	吴俣, 刘珏, 刘民, 等. 新型冠状病毒Omicron变异株的流行病学特征及防控研究[J]. 中国全科医学, 2022, 25(1): 14-19. DOI: 10.12114/j.issn.1007-9572.2021.00.348. Wu Y, Liu J, Liu M, et al. Epidemiologic features and containment of SARS-CoV-2 omicron variant[J]. Chinese General Practice, 2022, 25(1): 14-19. DOI: 10.12114/j.issn.1007-9572.2021.00.348.
[49]	杜敏, 刘民, 刘珏. 新型冠状病毒Delta变异株的流行病学特征及防控研究进展[J]. 中华流行病学杂志, 2021, 42(10): 1774-1779. DOI: 10.3760/cma.j.cn112338-20210808-00619. Du M, Liu M, Liu J. Progress in research of epidemiologic feature and control of SARS-CoV-2 Delta variant[J]. Chin J Epidemiol, 2021, 42(10): 1774-1779. DOI: 10.3760/cma.j.cn112338-20210808-00619.
[50]	Ayoubkhani D, Bosworth ML, King S, et al. Risk of long COVID in people infected with SARS-CoV-2 after two doses of a COVID-19 vaccine: community-based, matched cohort study[J]. medRxiv, 2022. DOI: 10.1101/2022.02.23.22271388.